ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

9 links0 made here, not in the record17 judgments2 judges (the rules as one: Rule based)5 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT03606967Testing the Addition of anIndividualized Vaccine toDurvalumab and Tremelimumaband Chemotherapy inPatients With MetastaticTriple Negative BreastCancerNational Cancer Institute (NCIPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 13 · ClinicalTrials.gov record · Version of 2026-10-13Nov 4 · ClinicalTrials.gov record · Version of 2026-11-04Nov 5 · ClinicalTrials.gov record · Version of 2026-11-05Nov 12 · ClinicalTrials.gov record · Version of 2026-11-12Nov 18 · ClinicalTrials.gov record · Version of 2026-11-18Version of 2026-11-18CONDITIONSTriple Negative Breast Neop…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSCarboplatinIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDurvalumabIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerGemcitabineEntry “Gemcitabine Hydrochloride”, re…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAlbumin-Bound PaclitaxelEntry “Nab-paclitaxel”, read by our n…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundINT009880Entry “Personalized Synthetic Long Pe…›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPoly ICLCIntervention entry›Nov 3 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSacituzumab govitecanIntervention entry›Nov 3 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionTremelimumabIntervention entry›Nov 3 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Carboplatin

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Carboplatin”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Background
Background · 2

All judgments on this study

WhenLinkJudgeDecisionState
Oct 13The record itselfClinicalTrials.gov recordVersion of 2026-10-13Record change
Nov 3CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 3DurvalumabClaude Opus 5.5Background · partnerCurrent
Nov 3GemcitabineClaude Opus 5.5BackgroundCurrent
Nov 3Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 3INT009880Claude Opus 5.5BackgroundCurrent
Nov 3Poly ICLCClaude Opus 5.5BackgroundCurrent
Nov 3Sacituzumab govitecanClaude Opus 5.5Background · optionCurrent
Nov 3TremelimumabClaude Opus 5.5Background · partnerCurrent
Nov 4The record itselfClinicalTrials.gov recordVersion of 2026-11-04Record change
Nov 5The record itselfClinicalTrials.gov recordVersion of 2026-11-05Record change
Nov 12The record itselfClinicalTrials.gov recordVersion of 2026-11-12Record change
Nov 18The record itselfClinicalTrials.gov recordVersion of 2026-11-18Record change
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18DurvalumabRule based · role ruleBackgroundAgrees
Nov 18GemcitabineRule based · role ruleBackgroundAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18INT009880Rule based · role ruleBackgroundAgrees
Nov 18Poly ICLCRule based · role ruleBackgroundAgrees
Nov 18Sacituzumab govitecanRule based · role ruleBackgroundAgrees
Nov 18TremelimumabRule based · role ruleBackgroundAgrees
As of nowTriple Negative Breast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.